Mackenzie Pellin, DVM, DACVIM (Oncology), DACVR (Radiation Oncology)

Department of Medical Sciences
Office: 4174

Mackenzie Pellin, DVM, DACVIM (Oncology), DACVR (Radiation Oncology)

Titles and Education

  1. Rotating Small Animal Medicine and Surgical Internship, 2011-2012
    Wheat Ridge Animal Hospital, Wheat Ridge, CO.  
  2. Doctor of Veterinary Medicine, 2011
    University of Wisconsin – Madison, Madison, WI
  3. Bachelor of Arts with Honors – Zoology, 2006
    University of Wisconsin – Madison, Madison, WI


Some of Dr. Pellin’s research interests include clinical trials to explore novel treatments or symptom management in oncology patients, collaborative research with other institutions to improve understanding of disease processes, and palliative & end-of-life care.


Dr. Pellin is a clinical professor who assists with training students and house officers on medical oncology and radiation oncology, in addition to seeing patients in UWVC. She is the residency director for the medical oncology residency program. She also teaches in the CAEM course, oncology selective, physical examination labs, and clinical introduction courses.

Clinical Interests

Dr. Pellin's clinical interests involved combining radiation therapy and medical management of oncology patients to improve disease response and quality of life, novel treatment and management options, and palliative care & end-of-life care for patients and their owners.

Graduate Training

Radiation Oncology residency, University of Wisconsin 2015-2017

Medical Oncology residency, University of Wisconsin 2012-2015

Rotating internship, Wheat Ridge Animal Hospital 2011-2012

Veterinary School, University of Wisconsin 2007-2011

Recent Publications

  1. Siewert J, Pellin MA, Husbands BD, Curran KM, Scavelli D, Sampene E. Feline cutaneous lymphoma: an evaluation of disease presentation and factors affecting response to treatment. J Feline Med Surg. 2022 Apr;24(4):389-397. doi: 10.1177/1098612X211028837. Epub 2021 Jul 21. PMID: 34284671.
  2. Keepman SJ, Pellin MA. Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats. J Feline Med Surg. 2021 Dec 18:1098612X211067023. doi: 10.1177/1098612X211067023. Epub ahead of print. PMID: 34923878.
  3. Murray CA, Willcox JL, De Mello Souza CH, Husbands B, Cook MR, Clifford C, Leeper H, Pellin M, Richardson D, Herrera CL, Krick E, McMillan S, Al-Nadaf S, Skorupski KA. Outcome in dogs with curative-intent treatment of localized primary pulmonary histiocytic sarcoma. Vet Comp Oncol. 2021 Dec 8. doi: 10.1111/vco.12791. Epub ahead of print. PMID: 34878710.
  4. Treggiari E, Pellin MA, Valenti P, Curran KM, Borrego JF, Romanelli G, Mason SL, Taylor A. Tolerability and outcome of palliative treatment for metastatic pulmonary carcinoma in cats. J Small Anim Pract. 2021 Nov;62(11):992-1000. doi: 10.1111/jsap.13421. Epub 2021 Oct 4. PMID: 34608648.
  5. Veluvolu S, Pellin M, Vos N. Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol. J Am Vet Med Assoc. 2021 Sep 1;259(5):494-502. doi: 10.2460/javma.259.5.494. PMID: 34388019.
  6. Vos N, Pellin M, Vail DM. A comparison of 12- and 19-week CHOP protocols using non-randomized, contemporaneous controls. Vet Comp Oncol. 2019 Sep;17(3):276-284. doi: 10.1111/vco.12465. Epub 2019 May 29. PMID: 31140707.
  7. Parachini-Winter C, Curran KM, Pellin M, Laver T, Hanot C, Vernier TH, Séguin B. Cutaneous and subcutaneous metastasis of appendicular osteosarcoma in dogs: 20 cases. J Vet Intern Med. 2019 Sep;33(5):2200-2208. doi: 10.1111/jvim.15557. Epub 2019 Jul 11. PMID: 31294875; PMCID: PMC6766478.
  8. Pellin, M. A., Wouda, R. M., Robinson, K., Tsimbas, K., Kurzman, I. D., Biller, B. J. and Vail, D. M. (2017), Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study. Vet Comp Oncol, 15: 919–931. doi:10.1111/vco.12232